In recent years, the, chimeric antigen receptor T (CAR-T) cell therapy as an adoptive immunotherapy has received great attention and made great breakthroughs. CAR-T cells show great specificity, targeting, and less major histocompatibility complex restriction in tumor immunotherapy, significantly different from traditional T cells.
In spite of the progress of CART-T technology in the treatment of lymphoma, leukemia, and other blood system tumor, there are still many difficulties in the treatment of solid tumors by CAR-T technology. In this review, we will make a brief summary of the present situation of CAR-T cells in the treatment of prostate cancer, and discuss the promise of the application of this technology to prostate cancer therapy.
OncoTargets and therapy. 2019 Jan 03*** epublish ***
Haiyuan Yu, Jun Pan, Zhicheng Guo, Chunhua Yang, Lijun Mao
Department of Urinary Surgery, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, China, , .